Literature DB >> 8699340

Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats.

N Sugioka1, H Koyama, T Ohta, H Kishimoto, T Yasumura, K Takada.   

Abstract

Mycophenolate mofetil (MPM), a new immunosuppressant, is the morpholinoethyl ester of mycophenolic acid (MPA). The distribution in blood and pharmacokinetics of MPA after administration of MPM were examined. The plasma to erythrocyte concentration ratio was low (0.10-0.15). MPA existed in rat plasma as the highly bound form (bound fraction was 9.79 +/- 0.57%). MPA disappeared from the systemic circulation with biexponential decay. After i.v. administration of MPM at the doses of 8.3, 16.7, and 33.3 mg/kg, the total clearance of MPA was 0.241 +/- 0.056, 0.321 +/- 0.126, and 0.317 +/- 0.092 L/h/kg, respectively. The terminal elimination half-live were 5.17 +/- 1.44, 8.89 +/- 2.76, and 7.94 +/- 2.94 h, respectively. After i.d. administration of MPM at the doses of 8.3, 16.7, 33.3, and 50.0 mg/kg, the terminal elimination half-live were 6.41 +/- 4.16, 4.49 +/- 2.20, 7.58 +/- 3.72, and 8.18 +/- 1.32 h, respectively. The mean peak times were within 30 min. The systemic availability of MPA after i.d. administration of MPM (at 8.3, 16.7, and 33.3 mg/kg) was calculated using the corresponding mean AUCiv, and the values were 84.3 +/- 35.0%, 69.9 +/- 25.7%, and 63.6 +/- 8.8%, respectively.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8699340     DOI: 10.1021/js9502480

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  1 in total

1.  Unexpectedly high exposure to enteric-coated mycophenolate sodium upon once-daily dosing.

Authors:  Guido Filler; Anita Lathia; Claire LeBlanc; Uwe Christians
Journal:  Pediatr Nephrol       Date:  2006-05-24       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.